<DOC>
	<DOCNO>NCT01967758</DOCNO>
	<brief_summary>This study patient brain tumor call astrocytic tumor . The study enroll patient receive standard treatment . The study test vaccine call ADU-623 . ADU-623 test human , goal study see ADU-623 give safely brain cancer patient well dose give patient among three dos plan test . This study also evaluate length time patient ' cancer worsen ADU-623 help patient live longer . The study also measure body 's immune system response ADU-623 .</brief_summary>
	<brief_title>Phase I Study Safety Immunogenicity ADU-623</brief_title>
	<detailed_description>This Phase I clinical trial examine safety , tolerability immunogenicity novel vaccine approach use live-attenuated strain Listeria monocytogenes express EGFRvIII NY-ESO-1 antigens induce proliferation memory effector T cell overall goal promote immune response high-grade astrocytic tumor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<criteria>Patients pathologic diagnosis WHO Grade III Grade IV astrocytic tumor complete standard care radiographic evidence progression follow standard care . Tumor tissue block available perform EGFRvIII NYESO1 test Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Karnofsky Performance Status ( KPS ) 70100 Age 18 year Have life expectancy 12 week Laboratory value ( perform within 5 day ) within designate range . For woman men childbearing potential , acceptable method highly effective contraception Ability give inform consent comply protocol . Have know allergy penicillin sulfa Have artificial ( prosthetic ) joint ( ) , orthopedic screw ( ) , metal plate ( ) exogenous implant ( ) device ( ) easily remove ( i.e. , prosthetic heart valve ) . Have evidence hepatic cirrhosis clinical radiographic ascites . Have radiographic clinically significant pleural effusion . Receipt prophylactic vaccine within 28 day study treatment . Unable avoid close contact another individual know high risk listeriosis ( e.g. , newborn infant , pregnant woman , HIVpositive individual ) . History allergy yeast component ADU623 vaccine ( e.g. , glycerol ) . Have immunodeficiency disease immunocompromised state ( e.g. , use immunosuppressive agent ; chemotherapy radiation therapy within 14 day study treatment ) . Have major surgery significant traumatic injury occur within 28 day treatment administration anticipate surgery procedure require general anesthesia study participation ( include 28 day last dose ADU623 ) . Use 4 gram per day acetaminophen . Have receive investigational product within 28 day study treatment plan receive within 28 day vaccine administration . Have unhealed surgical wound . Have clinically significant heart disease ( uncontrolled angina , myocardial infarction last 3 month , congestive heart failure New York Heart Association III IV ) . Have valvular heart disease require antibiotic prophylaxis prevention endocarditis . Have intercurrent illness either lifethreatening clinical significance might limit compliance study requirement include , limited , ongoing active infection , metabolic neurological disease , peripheral vascular disease psychiatric illness . Have insufficient peripheral venous access permit completion study dose compliance study phlebotomy regimen . Have receive diagnosis HIV , HCV , HBV ( patient hepatitis C antibody positive may enrol confirm negative viral load screen ) . Have active autoimmune disease history autoimmune disease require systemic steroid immunosuppressive treatment . Other medical psychiatric condition opinion Principal Investigator would preclude safe participation protocol . Pregnant lactate woman , treatment unknown effect embryo child . Patients require chronic corticosteroid use exclude may mask toxic effect relate vaccine may prevent development effective immune response follow vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Astrocytic Tumors</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Anaplastic Astrocytoma</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>